CTLA4 and neoplasm: The ORR was higher in the combined nivolumab/ipilimumab patients group and was not associated with a PD-L1 expression level on tumor cells, revealing a poor predictive potential of PD-L1 tumor expression for anti-PD-1 and anti-CTLA-4 combined therapy [28].